Colorectal Cancer

FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.

The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.

The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.

The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.

FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.

FDA clears Triton 1 robotic colonoscopy for screening and advanced therapy, backed by first-in-human data showing high detection rates and reduced clinician workload.

The FDA will use the extension to review additional data supporting the NDA for zanzalintinib plus atezolizumab for metastatic colorectal cancer.

NHIS analysis reveals major screening gaps for disabled adults—especially self-care limits—while at-home stool tests boost colorectal screening access.

Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor payload.

The sBLA for dostarlimab in dMMR/MSI-H rectal cancer is based on the AZUR-1 trial.

During a live event, Midhun Malla, MD, MS, and participants discussed toxicity considerations with third-line therapy selection for KRAS-mutant mCRC.

SimpleScreen CRC has demonstrated a sensitivity of 81.1% for CRC detection.

National BRFSS study reveals SOGI adults lag in cervical and breast cancer screening; gaps are linked to insurance, access, and stigma.

Dostarlimab previously received breakthrough therapy designation from the FDA for dMMR/MSI-H rectal cancer.

The results jeopardize the accelerated approval of adagrasib plus cetuximab for KRAS G12C–mutated mCRC.

Building on these data, the ongoing phase 3 BATTMAN trial is exploring botensilimab plus balstilimab in refractory MSS mCRC.

Myriad’s Precise MRD expands to breast, colorectal and renal cancers, using serial ctDNA tracking to spot residual disease and predict response.

It was previously shown that the STELLAR-303 trial achieved the coprimary end point of OS in the ITT population.

During a live event, Christopher Lieu, MD, and participants discussed selecting third-line therapy for KRAS-mutant metastatic colorectal cancer.

Blood-based T‑cell receptor sequencing reveals immune “fingerprints” in Lynch syndrome, helping track precancers early and paving the way for new cancer surveillance biomarkers.

During a live event, Christopher Lieu, MD, and participants discussed selecting third-line therapy for KRAS wild-type metastatic colorectal cancer.

The FDA has granted suplexa, a non-engineered autologous cellular immunotherapy, fast track designation for patients with MSI-H colorectal cancer.

Pelareorep plus FOLFIRI and bevacizumab showed durable responses in second-line RAS-mutant MSS metastatic colorectal cancer.